-+ 0.00%
-+ 0.00%
-+ 0.00%

MAIA Biotechnology Announces The Publication Of Preclinical Data For Its Lead Proprietary Telomere-Targeting THIO Dimer In The Peer-Reviewed Scientific Journal Naunyn-Schmiedeberg's Archives Of Pharmacology; Novel THIO Dimer Shows Promise As A New Compound With A Dual Mechanism Of Action For Enhancing Standard Cancer Treatments And Overcoming Resistance

Benzinga·03/20/2025 13:22:49
Listen to the news
  • Novel THIO dimer shows promise as a new compound with a dual mechanism of action for enhancing standard cancer treatments and overcoming resistance

MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announces the publication of preclinical data for its lead proprietary telomere-targeting THIO dimer in the peer-reviewed scientific journal Naunyn-Schmiedeberg's Archives of Pharmacology.

In a preclinical study, THIO and its new described dimer form were found to be potent inhibitors of Glutathione S-transferase Pi (GSTP1), a key enzyme implicated in cancer progression and chemoresistance and a highly important factor for the detoxification of cancer cells. The findings suggest that the dimerized form of THIO could enhance chemotherapeutic efficacy by effectively targeting GSTP1 and reducing drug resistance. The article, titled "Investigation of the inhibitory effects of the telomere-targeted compounds on glutathione S-transferase P1," was published on February 15, 2025.